Note 4.3 étoiles, basé sur 355 commentaires.
Hyperuricemia may be primary, tinnitus, inactivates mercaptopurine, Zyloprim Quebec, in the Zyloprim Quebec of Zyloprim, evaluation of liver function should be part of their diagnostic workup, as in gout. It has been reported that symptoms may sweetdevil2.000webhostapp.com is catalyzed by xanthine oxidase.
Zyloprim Description Zyloprim allopurinol has the following structural formula: Zyloprim is known chemically as 1,5-dihydro-4H-pyrazolo [3,4- d]pyrimidinone.
It is a xanthine oxidase inhibitor which is administered orally. Zyloprim – Clinical Pharmacology Zyloprim acts on purine catabolism, Zyloprim Quebec, without disrupting the biosynthesis of purines.
It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. It has been shown that reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by Zyloprim and oxipurinol.
This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis, Zyloprim Quebec. A maximum of 0, Zyloprim Quebec. The renal clearance of hypoxanthine and xanthine is at least 10 times greater than that of uric acid, Zyloprim Quebec.
The increased xanthine and hypoxanthine in the urine have not been accompanied Zyloprim Quebec problems of nephrolithiasis. Xanthine crystalluria has been reported in only three patients. The third patient had lymphosarcoma and produced an extremely large amount of uric acid because of rapid cell lysis during chemotherapy. Hyperuricemia may be primary, as in gout, or secondary to diseases such as acute and chronic leukemia, polycythemia vera, Zyloprim Quebec, multiple myeloma, and psoriasis.
Administration of Zyloprim generally results in a fall in Zyloprim quebec serum and urinary uric acid within 2 to 3 days. It has been postulated that this may be due to the mobilization of urate from tissue deposits as the serum uric acid level begins to fall. The action of Zyloprim differs from that of uricosuric agents, which lower the serum uric acid level by increasing urinary excretion of uric acid.
Zyloprim reduces both the serum and urinary uric acid levels by inhibiting the formation of uric acid. The use of Zyloprim to block the formation of urates avoids the hazard of increased renal excretion of uric acid posed by uricosuric drugs. Zyloprim can substantially reduce serum and urinary uric acid levels in previously refractory patients even in the presence of renal damage serious enough to render uricosuric drugs virtually ineffective.
Salicylates may be given conjointly for their antirheumatic effect without compromising the action of Zyloprim. This is in contrast to the nullifying effect of salicylates on uricosuric drugs.
Zyloprim – Clinical Pharmacology
Zyloprim also inhibits the enzymatic oxidation of mercaptopurine, the sulfur-containing analogue of hypoxanthine, Zyloprim Quebec, to 6-thiouric acid. This oxidation, which is catalyzed by xanthine oxidase, inactivates mercaptopurine. Zyloprim reduces serum and urinary uric acid concentrations. Zyloprim is indicated in: Treatment with Zyloprim should be discontinued when the potential for overproduction of uric acid is no longer present.
Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. Contraindications Patients who have developed a severe reaction to Zyloprim should not be restarted on the drug.
A few cases of reversible clinical hepatotoxicity have been noted in patients taking Zyloprim, and in some patients, asymptomatic rises in serum alkaline phosphatase or serum transaminase have been observed.
If anorexia, weight loss, or pruritus develop in patients on Zyloprim, evaluation of liver function should be part of their diagnostic workup. In patients with pre-existing liver disease, periodic liver function tests are recommended during the early stages of therapy. Due to the occasional occurrence of drowsiness, patients should be alerted to the need for due precaution when engaging in activities where alertness is mandatory.
Precautions GENERAL An increase in acute attacks of gout has been reported during the early stages of administration of Zyloprimeven when normal or subnormal serum uric acid levels have been attained.
Accordingly, maintenance Zyloprim Quebec of colchicine generally should be given prophylactically when Zyloprim is begun. Some patients with pre-existing renal disease or poor urate clearance have shown a rise in BUN during administration of Zyloprim. Renal failure in association with administration of Zyloprim has been observed among patients with hyperuricemia secondary to neoplastic diseases.
Concurrent conditions such as multiple myeloma and congestive myocardial disease were present among those patients whose renal dysfunction increased after Zyloprim was begun. Renal failure is also frequently associated with gouty nephropathy and rarely with hypersensitivity reactions associated with Zyloprim. Albuminuria has been observed Zyloprim Quebec patients who developed clinical gout following chronic glomerulonephritis and chronic pyelonephritis.
Patients with decreased renal function require lower doses of Zyloprim than those with normal renal function. In patients with severely impaired renal function or decreased urate clearance, Zyloprim Quebec, the half- life of oxipurinol in the plasma is greatly prolonged.
Bone marrow depression has been reported in patients receiving Zyloprim, most of whom received concomitant drugs with the potential for causing this reaction, Zyloprim Quebec.
Rarely, a patient may develop varying degrees of bone marrow depression, affecting one or more cell lines, while receiving Zyloprim alone, Zyloprim Quebec. Zyloprim and its primary active metabolite, oxipurinol, are eliminated by the kidneys; therefore, changes in renal function have a profound effect on dosage, Zyloprim Quebec. The prothrombin time should be reassessed periodically in the patients receiving dicumarol who are given Zyloprim.
It has been reported that Zyloprim prolongs the half-life of the anticoagulant, dicumarol. The clinical basis of this drug interaction has not been established but should be noted when Zyloprim is given to patients already on dicumarol therapy.
The concomitant Zyloprim Quebec of uricosuric agents and Zyloprim has been associated with a decrease in the excretion of oxypurines hypoxanthine and xanthine and an increase in urinary uric acid excretion compared with that observed with Zyloprim alone.
Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on Zyloprim alone or in combination with uricosuric agents, the possibility should be kept in mind. The reports that the concomitant use of Zyloprim and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with Zyloprim compared to patients who are not receiving Zyloprim quebec drugs, Zyloprim Quebec. The cause of the reported association has not been established. Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of Zyloprim. Tolbutamide’s conversion to inactive metabolites has been shown to be catalyzed by xanthine oxidase from rat liver, Zyloprim Quebec.
The clinical significance, if any, Zyloprim Quebec, of these observations is unknown. Chlorpropamide’s plasma half-life may be prolonged by Zyloprim, since Zyloprim and chlorpropamide may compete for excretion in the renal tubule, Zyloprim Quebec. The risk of hypoglycemia secondary to this mechanism may be increased if Zyloprim and chlorpropamide are given concomitantly in the presence of renal insufficiency. Rare reports indicate that cyclosporine levels may be increased during concomitant treatment with Zyloprim.
There are, however, no adequate or well-controlled studies in pregnant women, Zyloprim Quebec. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed, Zyloprim Quebec.
Experience with Zyloprim during human pregnancy has been limited partly because women of reproductive age rarely require treatment with Zyloprim. However, ina literature publication case report describes the outcome of a full term pregnancy in a 35 year-old woman who had recurrent kidney stones since age 18 who took allopurinol throughout the pregnancy. The child had multiple complex birth defects and died at 8 days of life. The overall rate of major fetal malformations and spontaneous abortions was reported to be within the normal expected range; Zyloprim Quebec, one child had severe malformations similar to those described in the cited earlier case report.
The most frequent adverse reaction to Zyloprim is skin rash. Skin reactions can be Zyloprim Quebec and sometimes fatal. Some patients with the most severe reaction also had fever, chills, Zyloprim Quebec, arthralgias, cholestatic jaundice, eosinophilia and mild leukocytosis or leukopenia.
The explanation for this decrease is not obvious. The incidence of skin rash may be increased in the presence of renal insufficiency. Drug rash with eosinophilia and systemic symptoms DRESS syndrome or Zyloprim Quebec hypersensitivity syndrome DHS has been reported in association with allopurinol use.
The syndrome includes many of the severe reactions described above, and is potentially life-threatening and fatal. The syndrome is often characterized by fever, severe and profuse skin rash, elevated leukocyte counts and in particular, elevated eosinophil counts, lymphadenopathy, and multi-organ pathologies, Zyloprim Quebec.
Systemic symptoms often included, but were not limited to, the hepatic and renal systems. Symptoms involving the cardiac, gastrointestinal, lymphatic, pulmonary, and ophthalmic systems were also reported as occurring as part of the syndrome.
It has been reported that symptoms may develop in approximately 1 week from initiating allopurinol therapy, but longer latency periods have also been reported, Zyloprim Quebec. Acute attacks of gout. The most frequent event observed was acute attacks of gout following the initiation of therapy.
Body As a Whole: Hepatic necrosis, granulomatous hepatitis, hepatomegaly, hyperbilirubinemia, cholestatic jaundice, vomiting, intermittent abdominal pain, gastritis, dyspepsia. Thrombocytopenia, eosinophilia, Zyloprim Quebec, leukopenia. Peripheral neuropathy, neuritis, paresthesia, somnolence.
Erythema multiforme exudativum Stevens-Johnson syndrometoxic epidermal necrolysis Lyell’s syndromehypersensitivity vasculitis, purpura, vesicular bullous dermatitis, exfoliative dermatitis, eczematoid dermatitis, pruritus, urticaria, alopecia, onycholysis, lichen planus. Pericarditis, peripheral vascular disease, thrombophlebitis, bradycardia, vasodilation. Infertility malehypercalcemia, gynecomastia male.
Hemorrhagic pancreatitis, gastrointestinal bleeding, stomatitis, salivary gland swelling, hyperlipidemia, tongue edema, anorexia. Aplastic anemia, agranulocytosis, eosinophilic fibrohistiocytic lesion of bone marrow, pancytopenia, prothrombin decrease, anemia, hemolytic anemia, Zyloprim Quebec, reticulocytosis, lymphadenopathy, lymphocytosis.
Optic neuritis, confusion, Zyloprim Quebec, dizziness, vertigo, foot drop, decrease in libido, depression, amnesia, tinnitus, asthenia, Zyloprim Quebec, insomnia.
Bronchospasm, Zyloprim Quebec, asthma, pharyngitis, rhinitis. Furunculosis, facial edema, sweating, skin edema. Cataracts, macular retinitis, iritis, conjunctivitis, amblyopia.
Nephritis, Zyloprim Quebec, impotence, primary hematuria, albuminuria. Overdosage Massive overdosing or acute poisoning by Zyloprim has not been reported. In the management of overdosage there is no specific antidote for Zyloprim. There has been no clinical experience in the management of a patient who has taken massive amounts of Zyloprim.
Both Zyloprim and oxipurinol are dialyzable; however, the usefulness of hemodialysis Zyloprim Quebec peritoneal Zyloprim Quebec in the management of an overdose of Zyloprim is unknown. Normal serum urate levels are usually achieved in 1 to 3 weeks.
It should also be noted that Zyloprim is generally better tolerated if taken following meals. A fluid Zyloprim Quebec sufficient to yield a daily urinary output of at least 2 liters and the maintenance of a neutral or, preferably, slightly alkaline urine are desirable.
The correct size and frequency of dosage for maintaining the serum uric acid just within the normal range is best determined by using the serum uric acid level as an index.